Effects of advanced glycated end-products on secretion of extracellular matrix metalloproteinase inducer and activity of matrix metalloproteinase-2 in mouse osteoblasts

Li WANG,Hui JIN,Zi-lin SUN,Rong-feng DAI,Rui-fang BU

DOI: https://doi.org/10.3760/cma.j.issn.1674-5809.2009.01.016

2009-01-01

Abstract:Objective To study the effect of advanced glycated end products (AGEs) on the secretion of extracellular matrix metalloproteinase inducer (EMMPR1N) and the activity of matrix metaUoproteinase-2 (MMP-2) in cultured mouse embryo/fetus calvaria osteoldasts (MC3T3-EI). Methods The AGEs-BSA was prepared by incubating bovine serum albumin (BSA) with glucose. The cultured MC3T3-E1 was added with AGEs-BSA (50, 100, 200, and 400 rag/L) for 24 h or 200 mg/L AGEs-BSA for 12, 24, and 48 h, respectively, taking DMEM and BSA as negative control. The concentration of EMMPRIN in the supernatant was quantified by ELISA. The activity of MMP-2 in MC3T3-E1 was determined by gelatin enzymogram method. MC3T3-EI was cultured in the presence of DMEM and AGEs-BSA (50 mg/L) with or without Anti-EMMPRIN antibody. The activity of MMP-2 in MC3T3-E1 was determined by gelatin enzymogram method. All statistical analyses were carried out with the SPSS 13.0. Statistical analysis was done by one-way analysis of variance (ANOVA). Results In different dose of AGEs group, the concentration of EMMPRIN in the supernatant ((7.34 ± 0.11), (10.86 ± 0.07), (14.48±0.14), and (15.43±0.23) μg/L) was higher than BSA group (q was 3.111, 3.090, 2.921, and4.387; P<0.05) and the activity of MMP-2 ((225.12±5.01), (305.83±5.21), (363.04± 8.04), and (410.63±16.84)INT · mm2) was significantly increased than BSA group(q was 3.109, 3.545, 5.912, and 5. 895; P < 0.05). In different time of AGEs group, the concentration of EMMPRIN in the superoatant ((12.41±0.02), (17.88±0.35), and (18.88±0.36) μg/L) was higher than BSA group (q was 5.522, and 7.462, 7.323, P < 0.05) and the activity of MMP-2 ((222.18±14.53), and (246.53±5.96) INT · mm2) was increased compared to BSA group (q was 4.159, and 4.321 ; P < 0.05). The activity of MMP-2 was significantly decreased in anti-EMMPRIN antibody-blocking group compared to the control groups ((543.21±67.90) and (867.95±113.46) INT · mm2, q =6.354, P <0.05) and 50 mg/L AGEs group ((127.63±11.36) and (160.76±17.45) INT · mm2, q =7.742, P < 0.05). Conclusions The AGEs could stimulate the expression of EMMPRIN and the activity of MMP-2 in cultured MC313-El, which may be partially inhibited by anti-EMMPRIN antibody. These findings suggest that EMMPRIN might mediate the role of AGEs in the development of osteoporosis by MMP-2.